open access
IPF and CPFE — the two different entities or two different presentations of the same disease?
open access
Abstract
In this article the co-existence of pulmonary emphysema with lung fibrosis of typical pattern and distribution for usual interstitial
pneumonia (UIP) was compared with idiopathic pulmonary fibrosis (IPF) alone. Author discusses the etiopathogenesis of these
diseases, differences in signaling pathways and the role of senescent cells. Moreover, clinical course, pulmonary function tests
as well as main complications are reviewed. However, the lack of well-established diagnostic criteria for CPFE along with mainly
retrospective character of the studies make current knowledge about this entity rather deficient.
Abstract
In this article the co-existence of pulmonary emphysema with lung fibrosis of typical pattern and distribution for usual interstitial
pneumonia (UIP) was compared with idiopathic pulmonary fibrosis (IPF) alone. Author discusses the etiopathogenesis of these
diseases, differences in signaling pathways and the role of senescent cells. Moreover, clinical course, pulmonary function tests
as well as main complications are reviewed. However, the lack of well-established diagnostic criteria for CPFE along with mainly
retrospective character of the studies make current knowledge about this entity rather deficient.
Keywords
idiopathic pulmonary fibrosis, IPF, combined pulmonary fibrosis and emphysema, CPFE
About this articleTitle
IPF and CPFE — the two different entities or two different presentations of the same disease?
Journal
Advances in Respiratory Medicine
Issue
Article type
Review paper
Pages
23-26
Published online
2017-12-29
DOI
10.5603/ARM.a2017.0049
Pubmed
Bibliographic record
Adv Respir Med 2018;86(1):23-26.
Keywords
idiopathic pulmonary fibrosis
IPF
combined pulmonary fibrosis and emphysema
CPFE
Authors
Sylwia Kwiatkowska
References (43)- Elicker B, Kallianos K, Henry T. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. European Respiratory Review. 2017; 26(144): 170008.
- Akira M, Inoue Y, Kitaichi M, et al. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings. Radiology. 2009; 251(1): 271–279.
- Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013; 266(3): 936–944.
- Jacob J, Bartholmai BJ, Rajagopalan S, et al. Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Med. 2016; 14(1): 190.
- Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med. 1990; 84(5): 365–369.
- Cottin V, Nunes H, Brillet PY, et al. Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26(4): 586–593.
- Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012; 141(1): 222–231.
- Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013; 41(5): 1207–1218.
- King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378(9807): 1949–1961.
- Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007; 293(3): L525–L534.
- Allen J, Spiteri M. Growth factors in idiopathic pulmonary fibrosis: relative roles. Repir Res. 2002; 3(1): 13.
- Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012; 122(8): 2756–2762.
- Thannickal VJ, Zhou Y, Gaggar A, et al. Fibrosis: ultimate and proximate causes. J Clin Invest. 2014; 124(11): 4673–4677.
- Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002; 3(5): 349–363.
- Houben JMJ, Mercken EM, Ketelslegers HB, et al. Telomere shortening in chronic obstructive pulmonary disease. Respir Med. 2009; 103(2): 230–236.
- Diaz de Leon A, Cronkhite JT, Katzenstein ALA, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010; 5(5): e10680.
- Armanios MY, Chen JJL, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007; 356(13): 1317–1326.
- Kuwano K, Araya J, Hara H, et al. Cellular senescence and autophagy in the pathogenesis of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Respir Investig. 2016; 54(6): 397–406.
- Álvarez D, Cárdenes N, Sellarés J, et al. IPF lung fibroblasts have a senescent phenotype. Am J Physiol Lung Cell Mol Physiol. 2017; 313(6): L1164–L1173.
- Wang C, Jurk D, Maddick M, et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell. 2009; 8(3): 311–323.
- Schafer MJ, White TA, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017; 8: 14532.
- Disayabutr S, Kim EK, Cha SI, et al. miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis. PLoS One. 2016; 11(6): e0158367.
- Kulkarni T, O'Reilly P, Antony VB, et al. Matrix Remodeling in Pulmonary Fibrosis and Emphysema. Am J Respir Cell Mol Biol. 2016; 54(6): 751–760.
- Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res. 2012; 13: 3.
- Königshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One. 2008; 3(5): e2142.
- Shi J, Li F, Luo M, et al. Distinct Roles of Wnt/β-Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Mediators Inflamm. 2017; 2017: 3520581.
- Togo S, Holz O, Liu X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med. 2008; 178(3): 248–260.
- Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med. 2016; 16(1): 137.
- Cottin V, Le Pavec J, Prévot G, et al. GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010; 35(1): 105–111.
- Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung. 2010; 188(5): 365–373.
- Todd NW, Jeudy J, Lavania S, et al. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair. 2011; 4(1): 6.
- Tzouvelekis A, Zacharis G, Oikonomou A, et al. Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med. 2013; 13: 31.
- Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013; 144(1): 234–240.
- Sato S, Tanino Y, Misa K, et al. Identification of Clinical Phenotypes in Idiopathic Interstitial Pneumonia with Pulmonary Emphysema. Internal Medicine. 2016; 55(12): 1529–1535.
- de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007; 132(6): 1932–1938.
- Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014; 108(3): 524–530.
- Oh SY, Kim MiY, Kim JE, et al. Evolving Early Lung Cancers Detected During Follow-Up of Idiopathic Interstitial Pneumonia: Serial CT Features. AJR Am J Roentgenol. 2015; 204(6): 1190–1196.
- Lee BW, Wain JC, Kelsey KT, et al. Association of cigarette smoking and asbestos exposure with location and histology of lung cancer. Am J Respir Crit Care Med. 1998; 157(3 Pt 1): 748–755.
- Otsuka H, Sugino K, Hata Y, et al. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema. Mol Clin Oncol. 2016; 5(3): 273–278.
- Sato S, Koike T, Hashimoto T, et al. Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema. Ann Thorac Cardiovasc Surg. 2016; 22(4): 216–223.
- Hata A, Sekine Y, Kota O, et al. Impact of combined pulmonary fibrosis and emphysema on surgical complications and long-term survival in patients undergoing surgery for non-small-cell lung cancer. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1261–1268.
- Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013; 85(4): 326–331.
- Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017; 50(1).